PERK protein mutant and application thereof in prevention of UVB-induced skin light injury reaction

By designing the truncated mutant of PERK protein, using genetic engineering technology to express and modify, a pharmaceutical composition is constructed to prevent UVB-induced skin photodamage, which solves the PERK protein research problem in the prior art and achieves antagonism of the UVB-induced photodamage response effect.

CN119060981AActive Publication Date: 2024-12-03ACADEMY OF MILITARY MEDICAL SCIENCES
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411235993.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-04
Publication Date
2024-12-03
Estimated Expiration
2044-09-04

AI Technical Summary

Technical Problem

It is difficult for the prior art to effectively study and prepare the PERK protein drugs, because their larger volume is not suitable for pharmacological studies, and lacks its truncated mutants to identify the functional domain and study the activity and stability of the protein.

Method used

Truncated mutants of the PERK protein, including encoding nucleic acids, vectors and recombinant host cells, are designed and provided, and are expressed and modified by genetic engineering techniques to construct pharmaceutical compositions to prevent UVB-induced skin light damage.

Benefits of technology

It provides a truncated mutant of PERK protein, which can antagonize the activation of the p53-PERP pathway and pro-apoptotic effects induced by UVB, and has potential application value for preventing and controlling UVB-induced photodamage response.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119060981A_ABST
    Figure CN119060981A_ABST
Patent Text Reader

Abstract

The invention provides a PERK protein mutant and application thereof in prevention of UVB-induced skin light injury reaction, coding nucleic acid of the PERK protein mutant, a recombinant vector containing the coding nucleic acid of the PERK protein mutant, a recombinant host cell containing the recombinant vector and a primer for amplifying the coding nucleic acid of the PERK protein mutant. The invention discloses a PERK protein C-terminal truncated mutant which can antagonize UVB-induced p53-PERP pathway activation and promote apoptosis effect, and the mutant has application value in prevention of UVB-induced skin light injury reaction and preparation of products for prevention of UVB-induced skin light injury.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of enzyme engineering and gene engineering, and specifically relates to a truncated mutant of PERK protein and application thereof. Background Art

[0002] Solar radiation is an important environmental risk factor that induces human skin damage, among which ultraviolet (UV) radiation is most closely related to photodamage. UV can be divided into long-wave ultraviolet (Ultraviolet A, UVA), medium-wave ultraviolet (Ultraviolet B, UVB) and short-wave ultraviolet (Ultraviolet C, UVC), and their effects on inducing skin photodamage reactions increase in sequence. However, since UVC can be filtered out by the ozone layer, its damaging effect directly reaching the earth's surface is weak. The damaging effect of UVB can be more than 1,000 times that of UVA, so UVB is recognized as the most destructive component of solar radiation to the human body. Studies have shown that UVB can destroy the structure and function of proteins, lipids and nucleic acids, thereby causing pathological damage reactions such as skin burns, blistering, dermatitis and even skin cancer. Therefore, the prevention and control strategies, technologies and drug research on UVB-induced photodamage effects have always attracted much attention.

[0003] p53 is a nuclear transcription factor with tumor suppressor function. In previous studies, our team revealed that UVB can upregulate the expression of apoptosis-specific target gene PERP by inducing p53 activation, and ultimately mediate the apoptosis-promoting effect on skin keratinocytes and stromal cells. This result provides a clear directional idea for the study of strategies to target the p53-PERP pathway and antagonize UVB-induced skin photodamage response. Previous studies screened p53 binding proteins and upstream protein kinases, and found that UVB can induce binding reactions with the endoplasmic reticulum (ER) stress-sensing protein PERK (protein kinase R-like ER kinase) in the process of inducing p53 activation and promoting cell apoptosis. PERK-mediated endoplasmic reticulum stress response plays an important regulatory role in cell survival and apoptosis response. Through research, it was found that PERK can bind to p53 under UVB stimulation and mediate its phosphorylation modification reaction and p53-PERP pathway activation reaction.

[0004] However, since the PERK protein is large and has thousands of amino acids, it is not suitable for drug preparation and pharmacological research, so its truncated mutants are urgently needed for subsequent functional studies. By designing truncated mutants, we can understand the functions of protein functional domains, determine which regions are essential structures, and the impact of this structure on the activity and stability of the entire protein, thus providing an important basis for protein structure and function research. Summary of the invention

[0005] In order to make up for the deficiencies of the prior art, the object of the present invention is to provide a truncated mutant of PERK protein and its application in preventing UVB-induced skin photodamage.

[0006] In order to achieve the above object, the present invention adopts the following technical solution:

[0007] In a first aspect, the present invention provides a truncated mutant of PERK protein, the amino acid sequence of the truncated mutant is shown in SEQ ID NO: 1 in the sequence listing.

[0008] The second aspect of the present invention provides a coding nucleic acid, a vector comprising the coding nucleic acid, or a recombinant host cell comprising the coding nucleic acid or the vector, wherein the coding nucleic acid can encode the truncated mutant described in the first aspect of the present invention, and its nucleotide sequence is shown in SEQ ID NO: 2 in the sequence listing.

[0009] The third aspect of the present invention provides a primer comprising a forward primer and a reverse primer, wherein the primer can amplify the encoding nucleic acid described in the second aspect of the present invention.

[0010] Furthermore, the nucleotide sequence of the forward primer is shown in SEQ ID NO: 3 in the sequence listing; the nucleotide sequence of the reverse primer is shown in SEQ ID NO: 4 in the sequence listing.

[0011] The fourth aspect of the present invention provides a derivative of the truncated mutant described in the first aspect of the present invention or the encoding nucleic acid described in the second aspect of the present invention.

[0012] Furthermore, the derivative is a truncated mutant or a coding nucleic acid and other substances in the form of adsorption, inclusion, or covalent binding.

[0013] Furthermore, the modification includes glycosylation, acylation, phosphorylation, acetylation, methylation, sulfation or hydroxylation.

[0014] Furthermore, the other substances include one or more components selected from the group consisting of free adjuvants, stabilizers, buffers, surfactants, salts and preservatives.

[0015] The fifth aspect of the present invention provides a pharmaceutical composition for preventing UVB-induced skin photodamage, the pharmaceutical composition comprising the truncated mutant described in the first aspect of the present invention; or the encoding nucleic acid described in the second aspect of the present invention; or the derivative described in the fourth aspect of the present invention.

[0016] Furthermore, the pharmaceutical composition also includes a pharmaceutically acceptable carrier.

[0017] The sixth aspect of the present invention provides a product for preventing UVB-induced skin photodamage, the product comprising the truncated mutant described in the first aspect of the present invention, the encoding nucleic acid described in the second aspect of the present invention, the derivative described in the fourth aspect of the present invention and / or the pharmaceutical composition described in the fifth aspect of the present invention.

[0018] The seventh aspect of the present invention provides the use of the truncated mutant described in the first aspect of the present invention, the encoding nucleic acid described in the second aspect of the present invention, the derivative described in the fourth aspect of the present invention and / or the pharmaceutical composition described in the fifth aspect of the present invention in the preparation of a product for preventing UVB-induced skin photodamage.

[0019] The eighth aspect of the present invention provides a method for preparing the truncated mutant described in the first aspect of the present invention, which method includes genetic engineering technology and artificial synthesis.

[0020] Furthermore, the genetic engineering technology refers to connecting the encoding nucleic acid described in the second aspect of the present invention with a vector to obtain the recombinant vector described in the second aspect of the present invention, transforming the recombinant vector into a host cell to obtain the recombinant host cell described in the second aspect of the present invention, and culturing, expressing and producing the truncated mutant described in the first aspect of the present invention in the recombinant host cell.

[0021] Advantages and beneficial effects of the present invention:

[0022] The present invention found that PERK can bind to p53 under UVB stimulation and mediate its phosphorylation modification reaction and p53-PERP pathway activation reaction. A PERK C-terminal mutant with the N-terminus removed is provided, which can antagonize UVB-induced p53-PERP pathway activation and cell apoptosis-promoting effects. This mutant has potential application value in preventing and controlling UVB-induced light damage reactions. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 This is the inducible binding reaction diagram of PERK and p53 in HaCaT cells before and after UVB stimulation for 12 hours. Figure 1 A in the figure is the immunoprecipitation reaction of p53 antibody. Figure 1 B in the figure is the immunoprecipitation reaction of PERK antibody. Figure 1C in the figure is the immunoprecipitation reaction of p53 antibody and PERK antibody in whole cell lysate;

[0024] Figure 2 This is a diagram of PERK-mediated UVB-induced p53-PERP pathway activation and cell apoptosis in HaCaT cells. Figure 2 A in the figure is the analysis of the changes in the induced activation of p53 and the induced expression level of PERP after knocking down the expression level of PERK. Figure 2 B in the figure is the analysis of cell apoptosis response after knocking down PERK expression level;

[0025] Figure 3 This is a structural analysis diagram of the inducible binding reaction between PERK and p53. Figure 3 A in the figure is the construction scheme of wild-type PERK and its truncated mutants. Figure 3 B in the figure is the differential analysis of the binding ability of wild-type PERK and its truncated mutants to p53;

[0026] Figure 4 This is a diagram analyzing the ability of PERK-M4 to regulate the activation of the p53-PERP pathway;

[0027] Figure 5 Graph analyzing the ability of PERK-M4 to regulate UVB-induced pro-apoptotic responses. DETAILED DESCRIPTION

[0028] The present invention is further described in detail below in conjunction with specific embodiments, and the examples provided are only for illustrating the present invention, rather than for limiting the scope of the present invention. The examples provided below can be used as a guide for further improvement by those of ordinary skill in the art, and do not constitute a limitation of the present invention in any way.

[0029] In the present invention, PERK includes wild type, also known as EIF2AK3, PEK, WRS. The term covers full-length, unprocessed PERK. The term covers, for example, PERK genes, human PERK, and PERK from any other vertebrate source, including mammals, such as primates and rodents (e.g., mice and rats). As a preferred embodiment, in the present invention, PERK is a human gene with a gene ID of 9451.

[0030] PERK-M includes mutants and fragments of PERK, and the term covers any form of PERK derived from processing in cells. The term covers naturally occurring variants of PERK (e.g., splice variants or allelic variants). The term covers, for example, mutants and fragments of human PERK, as well as mutants and fragments of PERK from any other vertebrate source, including mammals, such as primates and rodents (e.g., mice and rats). As a preferred embodiment, in the present invention, PERK-M is a mutant constructed by the construction scheme in Example 2, including truncated mutant PERK-M1 of 30-874 amino acids; truncated mutant PERK-M2 of 30-669 amino acids; truncated mutant PERK-M3 of 30-514 amino acids; truncated mutant PERK-M4 of 514-1116 amino acids.

[0031] In the present invention, "coding nucleic acid" refers to any polymer form having any length and consisting of ribonucleotides or deoxyribonucleotides. In the context of the present invention, it refers to a DNA sequence that is transcribed and translated into a polypeptide in a host cell when placed under the control of an appropriate regulatory sequence. The boundaries of the coding nucleic acid sequence are determined by the start codon at the 5' (amino) end and the translation stop codon at the 3' (carboxyl) end. The coding sequence may include, but is not limited to, prokaryotic sequences, cDNA from eukaryotic mRNA, genomic DNA sequences from eukaryotic (e.g., mammalian) DNA, and even recombinant DNA sequences. The transcription termination sequence will generally be located at the 3' of the coding sequence. In a specific embodiment of the present invention, the coding nucleic acid refers to a nucleic acid sequence that can encode a truncated mutant of the PERK protein described in the first aspect of the present invention. Once the coding sequence of the truncated mutant of the present invention is isolated, the truncated mutant can be obtained in large quantities using recombinant technology.

[0032] In the present invention, a vector comprising the encoding nucleic acid of the present invention is provided. The term "vector" refers to an artificial construct that can deliver and preferably express one or more target genes or sequences in a host cell. The vector of the present invention can be a plasmid vector, a viral vector, etc. In some embodiments, a vector refers to a straight or circular nucleic acid molecule that comprises a nucleic acid of the present invention that is operably connected to other segments of autonomous replication provided in a recombinant host cell, or an expression cassette according to a nucleic acid molecule. "Operably connected" means that the nucleic acid sequence of interest is connected to a regulatory sequence (e.g., in an in vitro transcription / translation system or when a vector is introduced into a host cell) in a manner that allows the expression of the nucleotide sequence.

[0033] In the present invention, the term "recombinant host cell" refers to the introduction of a vector into a host cell so that the recombinant host cell can transcribe the target nucleic acid sequence and / or translate the target protein. In the present invention, the recombinant host cell can be made to express the truncated mutants described in the first aspect of the present invention by such genetic engineering techniques. In one aspect of the present invention, the protein truncated mutants as claimed and described herein can be produced in mammalian host cells, for example, CHO cells or other cell lines, using recombinant techniques. Mammalian host cells and cell lines suitable for recombinant production of various different proteins are well known in the art.

[0034] In the present invention, the term "primer" refers to a macromolecule with a specific nucleotide sequence that is stimulated to synthesize at the start of nucleotide polymerization and is connected to the reactant in the form of hydrogen bonds. Such a molecule is called a primer. Primers are usually two artificially synthesized oligonucleotide sequences, one primer is complementary to a DNA template strand at one end of the target region, called an upstream primer; the other primer is complementary to another DNA template strand at the other end of the target region, called a downstream primer, which functions as the starting point for nucleotide polymerization, and nucleic acid polymerase can start synthesizing a new nucleic acid chain from its 3' end.

[0035] In the present invention, the term "derivative" refers to a substance formed by modification, adsorption, encapsulation, or covalent binding of the truncated mutant protein or encoding nucleic acid described in the present invention with other substances, which maintains the desired activity or characteristics of the protein or nucleic acid. In one embodiment of the present invention, the protein has co-translational and / or post-translational modifications, such as glycosylation, acylation, phosphorylation, acetylation, methylation, sulfation, or hydroxylation. These modifications can be obtained by production in mammalian cells or by in vitro site-directed modification of synthetic peptides. When the protein of the present invention has an amino acid substitution relative to a related reference sequence, the substitution is preferably a conservative amino acid substitution. The protein of the present invention may also include modified amino acids. Amino acid modifications may include, for example, phosphorylation, acetylation, methylation, amidation, or any other amino acid modification known in the art, as long as the protein maintains the desired characteristics.

[0036] In the present invention, the term "UVB" refers to medium-wave ultraviolet light (Ultraviolet B), with a wavelength of 280-320nm, which can promote mineral metabolism and the formation of vitamin D in the body, but can also cause skin tanning and cancer. The U.S. Department of Health and Human Services and the World Health Organization have both identified ultraviolet light as a proven human carcinogen. Ultraviolet radiation is considered to be the main cause of non-melanoma skin cancer (NMSC), including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). UVB is recognized as the most destructive component of solar radiation to the human body. UVB is the main cause of skin redness and sunburn, and often damages the more superficial surface layers of the skin. It plays a key role in the development of skin cancer and plays an important role in tanning and photoaging. Studies have shown that UVB can destroy the structure and function of proteins, lipids and nucleic acids, thereby causing pathological damage reactions such as skin burns, blistering, dermatitis and even skin cancer. Therefore, the prevention and control strategies, technologies and drug research of UVB-induced light damage effects have always attracted much attention.

[0037] In the present invention, the term "pharmaceutically acceptable carrier" refers to any pharmaceutical carrier that does not induce the production of antibodies harmful to the individual receiving the composition and can be administered without excessive toxicity. Suitable carriers can be large, slowly metabolized macromolecules, such as proteins, polysaccharides, polylactic acid, polyglycolic acid, polymeric amino acids and amino acid copolymers. Such carriers are well known to those of ordinary skill in the art. Pharmaceutically acceptable carriers in pharmaceutical compositions can contain fluids, such as water, saline, glycerol and ethanol. Auxiliary substances such as protein stabilizers, wetting agents or emulsifiers, pH buffer substances, etc. may also be present in such vehicles. In some embodiments, the truncated mutants, encoding nucleic acids, derivatives and / or pharmaceutical compositions described in the present invention can be optionally used together with one or more adjuvants, pharmaceutically acceptable carriers or excipients, such as stabilizers, buffers, surfactants, salts and / or preservatives.

[0038] The pharmaceutical composition of the present invention can also be used in combination with other drugs that resist UVB-induced light damage. Other anti-UVB-induced light damage compounds can be administered simultaneously with the main active ingredient (e.g., PERK-M4, a truncated mutant of PERK protein), or even administered simultaneously in the same composition. Other therapeutic compounds can also be administered separately in a separate composition or in a dosage form different from the main active ingredient. Partial doses of the main ingredient can be administered simultaneously with other anti-UVB-induced light damage compounds, while other doses can be administered separately.

[0039] In the present invention, "HaCaT cells" refer to human immortalized keratinocytes. The cell line is derived from the normal skin outside the lesion of a 62-year-old male with melanoma. It is an immortalized human keratinocyte that is naturally transformed after in vitro culture. It is also the first immortalized epidermal cell. HaCaT cells can be used to study the damage of ultraviolet rays to human skin keratin.

[0040] In the present invention, the term "immunoprecipitation" (IP) refers to a method of small-scale affinity purification of antigens using specific antibodies fixed on solid supports such as magnetic beads or agarose resins. Immunoprecipitation is one of the most commonly used methods when it is necessary to separate proteins and other biomolecules for immunoblotting or other detection techniques from cell or tissue lysates. Antibodies (monoclonal or polyclonal) to specific proteins are fixed on an insoluble support (such as agarose or magnetic beads) and then incubated with cell lysates containing the target protein. During the incubation period, the lysate is gently stirred to allow the target antigen to bind to the fixed antibody to form an antigen-antibody immune complex. Subsequently, the immune complex is eluted from the solid support and the properties of the target antigen are analyzed. Free unbound antibodies can also be added to the lysate to form immune complexes, and then the complexes are recovered using fillers. Although the pre-fixed antibody method is more commonly used for IP, if the concentration of the target protein is low and the binding affinity of the antibody to the antigen is weak, the method of using free antibodies to form immune complexes is better.

[0041] In the present invention, the term "siRNA" refers to small interfering RNA, which can regulate gene expression through a phenomenon known as RNA interference (RNA interference, RNAi). siRNA can be used as a tool to study the function of single genes in vivo and in vitro, and is an attractive new type of therapy, especially for the treatment of undruggable targets for cancer and other diseases. siRNA delivery systems are divided into non-viral delivery systems and viral delivery systems. Non-viral delivery systems include polymers; lipids; peptides, etc., which are widely studied siRNA delivery systems. The effective pharmacological use of siRNA requires a "carrier" that can deliver siRNA to its intended site of action. The carrier assembles siRNA into a supramolecular complex, which exhibits functional properties during the delivery process.

[0042] In the present invention, the term "WESTERN-BLOT" refers to the protein immunoblotting method, which uses polyacrylamide gel electrophoresis (SDS-PAGE), the detected object is protein, the "probe" is antibody, and the "development" uses labeled secondary antibody. SDS-PAGE can separate protein samples and transfer them to a solid phase carrier (such as nitrocellulose membrane). The solid phase carrier can adsorb proteins and keep the type of polypeptide separated by electrophoresis and its biological activity unchanged.

[0043] In the present invention, the term "phthalocyanine blue rejection test" is also known as "trypan blue rejection method", which refers to a method in which phthalocyanine blue can only dye dead cells blue but not live cells, which is a quick and easy method for detecting cell survival rate. The principle is that normal cells have a complete cell membrane structure, while the cell membrane structure of dead cells is destroyed. Phthalocyanine blue cannot pass through normal cell membranes, so normal cells are not stained by phthalocyanine blue, while dead cells can be stained blue by phthalocyanine blue.

[0044] The present invention will be further described in detail below in conjunction with the accompanying drawings and examples. The following examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. Simple improvements to the present invention made according to the essence of the present invention all belong to the scope of protection claimed in the present invention. It should be noted that the experimental methods in the following examples, unless otherwise specified, are conventional methods, and the materials and reagents used in the following examples, unless otherwise specified, are all obtained from commercial sources.

[0045] Example 1 Verification of the ability of PERK protein to bind to p53

[0046] 1. Establishment of UVB-induced skin photodamage model:

[0047] Human skin keratinocytes (HaCaT) were used as a model. The cells were irradiated with a UVB dose (0.5 kJ / m2) that has been shown in previous studies to induce apoptosis in HaCaT cells. The expression levels of related proteins and the cell apoptosis response were detected at a specified time period after irradiation.

[0048] 2. Verification of the ability of PERK protein to bind to p53:

[0049] 1) Collect HaCaT cells before and after UVB stimulation for 12 hours, lyse and take 500 mg of whole cell lysate for immunoprecipitation with anti-p53 antibody, and the immunoprecipitate is identified with anti-PERK antibody. The results are as follows: Figure 1 As shown in A.

[0050] 2) After obtaining the experimental results that p53 can bind to PERK under UVB stimulation, the reverse immunoprecipitation method was used for verification, that is, the whole cell extract was immunoprecipitated with anti-PERK antibody, and the immunoprecipitate was identified with anti-p53 antibody. Figure 1 As shown in B.

[0051] 3) In steps 1) and 2), the total protein expression levels of p53 and PERK and their phosphorylation-induced activation levels in the whole cell lysate were simultaneously detected. The results are as follows: Figure 1 As shown in C.

[0052] The above results indicate that PERK protein can induce binding to p53 after UVB stimulation.

[0053] 3. Knockdown of PERK protein verifies its role in the p53-PERP pathway and cell apoptosis response

[0054] 1) Transfect PERK siRNA into HaCaT cells.

[0055] 2) When PERK expression level was knocked down, the Western-BLOT method was used to detect the changes in the phosphorylation modification level of p53 and the expression level of PERP. The results are as follows: Figure 2 As shown in A.

[0056] 3) Phthalocyanine blue exclusion assay was used to detect changes in cell apoptosis. The results are as follows: Figure 2 As shown in B.

[0057] The above results indicate that PERK protein is a new upstream protein kinase that mediates UVB-induced p53 activation.

[0058] Example 2 Construction of PERK mutants and analysis of their p53 binding ability

[0059] 1. Construction of PERK truncated mutants

[0060] 1) According to the structural and functional domain characteristics of PERK protein, a series of PERK truncated mutants were constructed. The full-length PERK is 30-1116 amino acids; the truncated mutant PERK-M1 is 30-874 amino acids; the truncated mutant PERK-M2 is 30-669 amino acids; the truncated mutant PERK-M3 is 30-514 amino acids; the truncated mutant PERK-M4 is 514-1116 amino acids, such as Figure 3 As shown in A.

[0061] The primers for constructing the full-length and PERK mutants are as follows:

[0062] Table 1. Primer sequences of PERK full-length and truncated mutants

[0063]

[0064] 2) The above primer pairs were used to amplify the cDNA of each PERK mutant and inserted into the pcDNA3.1-FLAG empty vector to construct each expression plasmid.

[0065] 3) The full-length and PERK truncated mutant expression plasmids were co-expressed with the HA-p53 expression plasmid in HaCaT cells, and the whole cell lysate was taken and immunoprecipitated with anti-p53 antibody. The immunoprecipitate was identified with anti-FLAG antibody; PERK mutants that lost the ability to bind to p53 were screened. The results were as follows: Figure 3 As shown in B.

[0066] The above results indicate that the N-terminus of PERK mediates its binding reaction with p53, and thus the C-terminal mutant of PERK (PERK-M4) completely loses its p53 binding reactivity.

[0067] Example 3 Analysis of the apoptotic response of PERK-M4 mutant to UVB-treated HaCaT cells

[0068] 1. In HaCaT cells with knocked-down PERK expression levels, full-length PERK and PERK mutants that lost the ability to bind to p53 were complemented, and the difference in the ability of wild-type and mutant PERK in mediating UVB-induced p53-PERP pathway activation before and after UVB irradiation was detected by the Western Blot method. The results are as follows Figure 4 As shown, compared with wild-type PERK, PERK-M4 lost the function of activating p53 and inducing PERP expression.

[0069] 2. The phthalocyanine blue exclusion experiment was used to detect the difference in the ability of wild-type and mutant PERK in mediating UVB-induced cell apoptosis before and after UVB irradiation. The results are as follows Figure 5 As shown, PERK-M4 can antagonize UVB-induced pro-apoptotic responses.

[0070] The above results show that the C-terminal PERK truncated mutant PERK-M4 has the function of targeting p53 and antagonizing UVB-induced skin keratinocyte apoptosis. The amino acid sequence, nucleotide sequence and the sequences of the amplification primers of the full length and each mutant of PERK-M4 in the present invention are shown in Table 2.

[0071] Table 2. PERK related sequence list

[0072]

[0073]

[0074]

[0075]

[0076] The present invention has been described in detail above. For those skilled in the art, without departing from the purpose and scope of the present invention, and without the need to carry out unnecessary experimental conditions, the present invention can be implemented in a wide range under equivalent parameters, concentrations and conditions. Although the present invention provides embodiments, it should be understood that the present invention can be further improved. In a word, according to the principles of the present invention, the application is intended to include any changes, uses or improvements to the present invention, including departure from the disclosed scope in the application, and changes made with conventional techniques known in the art.

Claims

1. A truncated mutant of PERK protein, characterized in that: The amino acid sequence of the truncated mutant is shown in SEQ ID NO: 1 in the sequence listing.

2. A coding nucleic acid, a recombinant vector comprising the coding nucleic acid, or a recombinant host cell comprising the coding nucleic acid or the vector, characterized in that: The encoding nucleic acid can encode the truncated mutant according to claim 1, and its nucleotide sequence is shown in SEQ ID NO: 2 in the sequence listing.

3. A primer comprising a forward primer and a reverse primer, characterized in that: The primers can amplify the encoding nucleic acid of claim 2; The nucleotide sequence of the forward primer is shown in SEQ ID NO: 3 in the sequence listing; The nucleotide sequence of the reverse primer is shown in SEQ ID NO: 4 in the sequence listing.

4. A truncated mutant according to claim 1 or a derivative of the encoding nucleic acid according to claim 2, characterized in that: The derivative is a truncated mutant or a coding nucleic acid formed by modification, adsorption, inclusion, or covalent binding with other substances; The modification includes glycosylation, acylation, phosphorylation, acetylation, methylation, sulfation or hydroxylation; The other substances include one or more components selected from the group consisting of free adjuvants, stabilizers, buffers, surfactants, salts and preservatives.

5. A pharmaceutical composition for preventing UVB-induced skin photodamage, characterized in that: The pharmaceutical composition comprises the truncation mutant according to claim 1; or Contains the encoding nucleic acid of claim 2; or Comprising the derivative according to claim 4.

6. The pharmaceutical composition according to claim 5, characterized in that The pharmaceutical composition may further include a pharmaceutically acceptable carrier or excipient, such as a stabilizer, a buffer, a surfactant, a salt and / or a preservative.

7. A product for preventing UVB-induced skin photodamage, characterized in that: The product comprises the truncated mutant according to claim 1, the encoding nucleic acid according to claim 2, the derivative according to claim 4 and / or the pharmaceutical composition according to any one of claims 5-6.

8. Use of the truncated mutant according to claim 1, the encoding nucleic acid according to claim 2, the derivative according to claim 4 and / or the pharmaceutical composition according to claims 5-6 in the preparation of a product for preventing UVB-induced skin photodamage.

9. A method for preparing the truncated mutant according to claim 1, characterized in that: The method includes genetic engineering technology and artificial synthesis.

10. The method according to claim 9, characterized in that The genetic engineering technology refers to connecting the encoding nucleic acid described in claim 2 with a vector to obtain the recombinant vector described in claim 2, transforming the recombinant vector into a host cell to obtain the recombinant host cell described in claim 2, and culturing, expressing and producing the truncated mutant described in claim 1 in the recombinant host cell.

Citation Information

Patent Citations

  • Method for screening an agent preventing or treating cancer using glycyl-tRNA synthetase and cadherin

    CN103959066A

  • Antisense oligomers for treatment of non-sense mediated rna decay based conditions and diseases

    CN111936163A

  • PERK as a target for virus therapeutics

    US20220202849A1